Second Expert Meeting on Chemical Substance Management for FY2026: Materials

Key News Points

At the second expert meeting on chemical substance management for FY2026, the importance of chemical substance management in medical institutions was re-emphasized. In particular, the value of choosing third-party succession over closure or discontinuation of business for medical institutions was a key point of discussion. The recommendation was made for chairpersons and directors to prepare over a 5-10 year span starting around age 60. The utilization of support organizations specializing in the medical industry is also considered important.

M&A Medical Editorial Department’s Perspective

The materials from this expert meeting can be said to have highlighted the importance of business continuity for medical institutions, particularly third-party succession, from the perspective of chemical substance management. This suggests that it is time to seriously consider business succession through M&A, not just from the viewpoint of regulatory compliance, but also to fulfill the responsibility as providers of regional healthcare, preceding the options of closure or discontinuation. Preparation over a 10-year span starting around age 60 serves as a realistic roadmap for medical institutions facing a lack of successors to achieve smooth succession while continuing to provide services to local residents. The utilization of specialized advisors is indispensable for understanding the complex management issues and regulations unique to medical institutions and for constructing the optimal scheme, making the role of specialized intermediaries like M&A Medical increasingly important.

Points Raised by This News

• The strengthening of chemical substance management may affect the assessment of business continuity for medical institutions.
• The importance of third-party succession as an alternative to closure or discontinuation of business was suggested at a public expert meeting.
• Business succession preparation over a 10-year span starting around age 60 is a realistic approach to maintaining regional healthcare.
• The utilization of industry-specific advisors is essential for resolving issues unique to medical institutions.

Practical Questions Arising from This News

• Can deficiencies in chemical substance management be a concern during M&A due diligence?
• What are the specific schemes for third-party succession?
• At what point should one consult with experts to protect regional healthcare?

If You Feel “Should I Consult Too?”

This may be the time to consider business succession as an option other than closure or discontinuation of business, if your institution’s chairperson or director is around 60 years old and faces a lack of successors or future concerns, from the perspective of regulatory compliance including chemical substance management and contribution to regional healthcare. We recommend first consulting with experts well-versed in medical M&A to explore the possibilities of an optimal succession plan tailored to your institution’s situation.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success-fee basis as an M&A support organization certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here